KRAS and neoplasm: Specifically, the KRAS and TP53 mutations we identified are previously described as functionally acquired mutations that lead to sustained activation of the PI3K/Akt signaling pathway, leading to early onset of a variety of tumor types.[11–14] Therefore, early detection and intervention seems to be essential for patients with GS.